ArticleSleep & breathing = Schlaf & Atmung2026
The growing burden of coexisting sleep apnea and acute myocardial infarction among adults aged 55 years and older in the United States, 2006-2023.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSleep apnea (SA) is a highly prevalent condition in the United States and increases mortality risk in patients with acute myocardial infarction (AMI). We examined demographic and geographic national trends in mortality involving both SA and AMI from 2006 to 2023.
methodThis cross-sectional, population-based study used death certificates from the CDC WONDER database (2006-2023) mentioning both SA and AMI to assess mortality involving both conditions among adults aged ≥ 55 years using ICD-10 codes I21-I22 (AMI) and G47.3 (SA). Age-adjusted mortality rates (AAMRs) per million with 95% CIs were analyzed, and annual percentage changes (APCs) were calculated using Joinpoint regression across demographic and geographic subgroups.
resultFrom 2006 to 2023, 18,388 deaths involving both SA and AMI occurred. While AMI-related mortality declined over time, mortality involving both SA and AMI increased. AAMRs involving both SA and AMI rose from 2006 to 2018 (APC: 5.07; 95% CI: 4.54 to 5.50), showed a steeper increase from 2018 to 2021 (APC: 13.71; 95% CI: 11.30 to 15.29), then declined by 2023 (APC:-6.46; 95% CI: -8.98 to -3.99). AAMRs among men were nearly three times those of women. Non-Hispanic (NH) Whites and NH Blacks had the highest AAMRs, while Hispanics had the lowest. The Midwest had the highest regional AAMR and the Northeast the lowest, while South Dakota and Nevada had the highest and lowest state-level AAMRs, respectively. From 2006 to 2020, rural areas showed higher AAMRs than urban areas.
conclusionWhile AMI-related mortality declined, mortality involving both SA and AMI increased from 2006 to 2021, with a decline from 2021 to 2023. Disparities persisted in men, NH Whites and NH Blacks, and those in the Midwest and rural areas. Whether targeted strategies, such as rigorous SA screening and prompt treatment, can reduce this growing burden warrants further study.
Indexed as
Identifiers
42982931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.